In situ-forming oleogel implant for rivastigmine delivery

Pharmaceutical Research

Volumn 25, Issue 4, 2008, Pages 845-852

  Vintiloiu, Anda ^a   Lafleur, Michel ^a   Bastiat, Guillaume ^a   Leroux, Jean Christophe ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Alzheimer's disease; Implant; Organogel; Rivastigmine; Sustained release

Indexed keywords

ESTER DERIVATIVE; HYDROGEN TARTRATE; OLEOGEL; RIVASTIGMINE; SAFFLOWER OIL; SODIUM CHLORIDE; TARTARIC ACID DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD RHEOLOGY; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG FORMULATION; DRUG IMPLANT; GEL; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; TRANSITION TEMPERATURE;

ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CHOLINESTERASE INHIBITORS; DRUG COMPOUNDING; DRUG IMPLANTS; INJECTIONS, SUBCUTANEOUS; MALE; MICROSCOPY, ELECTRON, SCANNING; NEUROPROTECTIVE AGENTS; ORGANIC CHEMICALS; PHENYLCARBAMATES; RATS; RATS, LONG-EVANS; RHEOLOGY; SAFFLOWER OIL; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL; TRANSITION TEMPERATURE;

EID: 43349089561     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-007-9384-3     Document Type: Article

References (31)

1. C. Mount and C. Downton. Alzheimer disease: progress or profit? Nat. Med. 12:780-784 (2006).
2. R. Katzman. Alzheimer's disease. NEJM 314:964-973 (1986).
3. C. G. Ballard. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur. Neurol. 47:64-70 (2002).
4. A. Lleo, S. M. Greenberg, and J. H. Growdon. Current pharmacotherapy for Alzheimer's disease. Ann. Rev. Med. 57:513-533 (2006).
5. S. Gauthier. Long-term efficacy of cholinesterase inhibitors. Brain Aging 2:9-22 (2002).
6. V. W. DeLaGarza. Pharmacologic treatment of Alzheimer's disease: an update. Am. Fam. Physician. 68:1365-1372 (2003).
7. V. Cotrell, K. Wild, and T. Bader. Medication management and adherence among cognitively impaired older adults. J. Gerontol. Soc. Work 47:31-46 (2006).
8. D. G. Wilkinson, A. P. Passmore, R. Bullock, S. W. Hopter, R. P. Smith, F. C. Protocnik, C. M. Maud, I. Engelbrecht, C. Hock, J. R. Ieni, and R. S. Bahra. A mutinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int. J. Clin. Pract. 56:441-446 (2002).
9. G. Singh, S. K. Thomas, S. Arcona, V. Lingala, and A. Mithal. Treatment persistency with rivastigmine and donepezil in a large state medicaid program. J. Am. Geriatr. Soc. 53:1269-1270 (2005).
10. K. L. Lanctôt, N. Herrmann, K. K. Yau, L. R. Khan, B. A. Liu, M. M. Loulou, and T. R. Einarson. Efficacy and safety of choliesterase inhibitors in Alzheimer's disease: a meta-analysis. Can. Med. Assoc. J. 169:557-564 (2003).
11. J. Birks, J. Grimley Evans, V. Iakovidou, and M. Tsolaki. Rivastigmine for Alzheimer's disease. Cochrane Database Syst. Rev. 4:CD001191 (2000).
12. W. H. Liu, J. L. Song, K. Liu, D. F. Chu, and Y. X. Li. Preparation and in vitro and in vivo release studies of huperzine A loaded microspheres for the treatment of Alzheimer's disease. J. Control Release 107:417-427 (2005).
13. X. Fu, Q. Ping, and Y. Gao. Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres. J. Microencapsul. 22:705-714 (2005).
14. P. Gao, P. Ding, H. Xu, Z. Yuan, D. Chen, J. Wei, and D. Chen. In vitro and in vivo characterization of huperzine A loaded microspheres made from end-group uncapped poly(d,l-lactide acid) and poly(d,l-lactide-co-glycolide acid). Chem. Pharm. Bull. 54:89-93 (2006).
15. Q. Yang, D. Williams, G. Owusu-Ababio, N. K. Ebube, and M. J. Habib. Controlled release tacrine delivery system for the treatment of Alzheimer's disease. Drug Deliv. 8:93-98 (2001).
16. F. L. Tse, and R. Laplanche. Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharm. Res. 15:1614-1620 (1998).
17. V. R. Sinha, and A. Trehan. Biodegradable microspheres for protein delivery. J. Control Release 90:261-280 (2003).
18. C. B. Packhaeuser, J. Schnieders, C. G. Oster, and T. Kissel. In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. 58:445-455 (2004).
19. S. Bhattacharya, and Y. Krishnan-Gosh. First report of phase selective gelation of oil from oil/water mixture. Possible implications toward containing oil spills. Chem. Commun. 2:185-186 (2001).
20. A. C. Couffin-Hoarau, A. Motulsky, P. Delmas, and J. C. Leroux. In situ-forming pharmaceutical organogels based on the self assembly of l-alanine derivatives. Pharm. Res. 21:454-457 (2004).
21. A. Motulsky, M. Lafleur, A. C. Couffin-Hoarau, D. Hoarau, F. Boury, J. P. Benoit, and J. C. Leroux. Characterization and biocompatibility of organogels based on l-alanine for parenteral drug delivery implants. Biomaterials 26:6242-6253 (2005).
22. F. Plourde, A. Motulsky, A. C. Couffin-Hoarau, D. Hoarau, H. Ong, and J. C. Leroux. First report on the efficacy of l-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs. J. Control Release 108:433-441 (2005).
23. K. Fredholt, D. H. Larsen, and C. Larsen. Modification of in vitro drug release rate from oily parenteral depots using a formulation approach. Eur. J. Pharm. Sci. 11:231-237 (2000).
24. B. M. Rao, M. K. Srinivasu, K. P. Kumar, N. Bhradwaj, R. Ravi, P. K. Mohakhud, G. O. Reddy, and P. R. Kumar. A stability indicating LC method for rivastigmine hydrogen tartrate. J. Pharm. Biomed. Anal. 37:57-63 (2005).
25. S. M. Nuno-Donlucas, J. C. Sanchez-Diaz, M. Rabelero, J. Cortes-Ortega, C.C. Luhrs-Olmos, V. V. Fernandez-Escamilla, E. Mendizabal, and J. E. Puig. Microstructured polyacrylamide hydrogels made with hydrophobic nanoparticles. J. Colloid. Interface Sci. 270:94-98 (2004).
26. R. Schmidt, M. Schmutz, M. Michel, G. Decher, and P. J. Mesini. Organogelation properties of a series of oligoamides. Langmuir 18:5668-5672 (2001).
27. M. R. Farlow. Update on rivastigmine. Neurology 9:230-234 (2003).
28. Novartis. Exelon TM: Rivastigmine hydrogen tartrate, cholinesterase inhibitor, Compendium of pharmaceutical specialties (CPS), Canadian Pharmacists Association, Ottawa, pp 835-840 (2004).
29. S. W. Coppack, T. J. Yost, R. M. Fisher, R. H. Eckel, and J. M. Miles. Periprandial systemic and regional lipase activity in normal humans. Am. J. Physiol. 270:E718-E722 (1996).
30. B. Jeong, Y. K. Choi, Y. H. Bae, G. Zentner, and S. W. Kim. New biodegradable polymers for injectable drug delivery systems. J. Control Release 62:109-114 (1999).
31. L. Appel, K. Engle, J. Jensen, L. Rajewski, and G. Zentner. An in vitro model to mimic in vivo subcutaneous monoolein degradation. Pharm. Res. 11:S-217 (1994).